ArticlePloS one2025
Monocyte distribution width enhances the detection of infection in patients after primary percutaneous coronary intervention.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonocyte distribution width (MDW) may serve as an infection marker in acute myocardial infarction (AMI) patients undergoing primary percutaneous coronary intervention (PCI), where infection rates range from 2.4% to 16.6%. We evaluated the association of increased MDW levels with infection occurrence and to assess MDW-based models for predicting infection risk and prolonged hospital length of stay (LOS) ≥ 7 days. METHODS AND
resultsThis retrospective cohort study included AMI patients undergoing PCI at a Taiwanese tertiary teaching hospital from January 1, 2020, to September 30, 2021. Logistic regression models incorporating MDW, Quick Sequential Organ Failure Assessment (qSOFA) score, age, and C-reactive protein (CRP) levels were compared to the Canada Acute Coronary Syndrome (C-ACS) score and stress hyperglycemia ratio (SHR). Among 252 patients, 12.7% developed infections, a rate that falls within the expected range. Infections were more frequent among patients with LOS ≥ 7 days (42.9% vs. 1.1%). A three-parameter model (qSOFA score ≥2, age ≥ 65, and MDW ≥ 20) demonstrated good performance for new infection (AUC: 0.834) and LOS ≥ 7 days (AUC: 0.714). Adding CRP ≥ 2 mg/dL improved predictions for infection (AUC: 0.909) and LOS ≥ 7 days (AUC: 0.798), outperforming the C-ACS score (AUC: 0.807) and SHR (AUC: 0.784).
conclusionMDW emerges as a promising biomarker for assessing the risks of infection and prolonged hospital LOS in patients with AMI. Its early use may facilitate timely clinical interventions, including earlier initiation of antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.